Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue

Journal of Endocrinology

Volumn 184, Issue 3, 2005, Pages 505-513

  Uckaya G ^a   Delagrange, P ^b   Chavanieu, A ^c   Grassy, G ^c   Berthault, M F ^c   Ktorza, A ^c   Cerasi, E ^a   Leibowitz, G ^a   Kaiser, N ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b IRIS   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HUMAN INSULIN; INSULIN; LEPTIN; S 23521; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DEGRANULATION; DIET; DISEASE COURSE; DISEASE EXACERBATION; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; METABOLISM; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PSAMMOMYS OBESUS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; GERBILLINAE; GLUCAGON; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; LEPTIN; MALE; MODELS, ANIMAL; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 15844389890     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.05818     Document Type: Article

References (42)

1. Buteau J, Roduit R, Susini S & Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42 856-864.
2. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ & Prentki M 2001 Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50 2237-2243.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA & Butler PC 2003 Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 102-110.
4. Cerasi E 1995 Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia 38 992-997.
5. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A & Halter JB 2003 The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52 1786-1791.
6. Deacon CF, Johhnsen AH & Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism 80 952-957.
7. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinmann BH, Vella A & Camilleri M 2002 Effect of GLP-1 on gastric volume, emptying, maximum volume ingested and postprandial symptoms in humans. American Journal of Physiology Gastrointestinal and Liver Physiology 282 G424-G431.
8. Donath MY, Gross DJ, Cerasi E & Kaiser N 1999 Hyperglycemiainduced b cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48 738-744.
9. Donath MY, Storling J, Maedler K & Mandrup-Poulsen T 2003 Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. Journal of Molecular Medicine 81 455-470.
10. Drucker DJ 2001 Minireview: the glucagon-like peptides. Endocrinology 142 521-527.
11. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U & Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 4397-4408.
12. Flint A, Raben A, Astrup A & Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppressesenergy intake in humans. Journal of Clinical Investigation 101 515-520.
13. Gadot M, Leibowitz G, Shafrir E, Cerasi E, Gross D & Kaiser N 1994 Hyperproinsulinemia and insulin deficiency in the diabetic Psammomys obesus. Endocrinology 135 610-616.
14. Gadot M, Ariav Y, Cerasi E, Kaiser N & Gross D 1995 Hyperproinsulinemia in the diabetic Psammomys obesus is a result of increased secretory demand on the B-cell. Endocrinology 136 4218-4223.
15. Gavrieli Y, Sherman Y & Ben Sasson SA 1992 Identification of programmed cell death in vitro via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 199 493-501.
16. Gross DJ, Leibowitz G, Cerasi E & Kaiser N 1996 Increased susceptibility of islets from diabetes-prone Psammomys obesus to the deleterious effects of chronic glucose exposure. Endocrinology 137 5610-5615.
17. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J & Beglinger C 1999 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. American Journal of Physiology - Regulatory Integrative and Comparative Physiology 276 R1541-R1544.
18. Hui H, Yu R, Bousquet C & Perfetti R 2002 Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 143 3529-3539.
19. Ishihara H, Maecler P, Gjinovci A, Herrera PL & Wollheim CB 2003 Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nature Cell Biology 5 330-335.
20. Kahn SE 2003 The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46 3-19.
21. Kaiser N, Leibowitz G & Nesher R 2003 Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. Journal of Pediatric Endocrinology and Metabolism 16 5-22.
22. Kalderon B, Gutman A, Levy E, Shafrir E & Adler JH 1986 Characterization of stages in development of obesity-diabetes syndrome in the sand rat (Psammomys obesus). Diabetes 35 717-723.
23. Larsen PJ, Fledelius C, Knudsen LB & Tang-Christensen M 2001 Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 50 2530-2539.
24. Leibowitz G, Ferber S, Apelqvist A, Edlund H, Gross DJ, Cerasi E, Melloul D & Kaiser N 2001a IPF1/PDX1 deficiency and beta-cell dysfunction in Psammomys obesus, an animal with type 2 diabetes. Diabetes 50 1799-1806.
25. Leibowitz G, Yuli M, Donath MY, Nesher R, Melloul D, Cerasi E, Gross DJ & Kaiser N 2001b Beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes 50 (Suppl 1) 113-117.
26. Li Y, Hansotia T, Yusta B, Ris F, Halban PA & Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. Journal of Biological Chemistry 278 471-478.
27. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A, Kaiser N & Donath MY 2001 Glucose induces beta-cell apoptosis via upregulation of the FAS receptor in human islets. Diabetes 50 1638-1690.
28. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA & Donath MY 2002 Glucose-induced beta cell production of IL-1 beta contributes to glucotoxicity in human islets. Journal of Clinical Investigation 110 851-860.
29. Marshak S, Totary H, Cerasi E & Melloul D 1996 Purification of the beta-cell glucose-sensitive factor that transactivates the insulin gene differentially in normal and transformed islet cells. PNAS 93 15057-15062.
30. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE & Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88 2719-2725.
31. de Menthière SC, Chavanieu A, Grassy G, Dalle S, Salazar G, Kervran A, Pfeiffer B, Renard P, Delagrange P, Manechez D et al. 2004 Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. European Journal of Medicinal Chemistry 39 473-480
32. Movassat J, Lopez AD, Beattie GB & Hayek A 2001 Exendin-4 upregulates expression of PDX-1 and hastens differentiation and maturation of human fetal pancreatic B cells. Diabetes 50 (Suppl 2) A341.
33. Nesher R, Gross DJ, Donath MY, Cerasi E & Kaiser N 1999 Interaction between genetic and dietary factors determines β-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 48 731-737.
34. Paris M, Bernard-Kragar C, Berthault MF, Bouwens L & Ktorza A 2003 Specific and combined effects of insulin and glucose on functional pancreatic β-cell mass in vivo in adult rats. Endocrinology 144 2717-2727.
35. Perfetti R, Zhou J, Doyle ME & Egan JM 2000 Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141 4600-4605.
36. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL & Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2 1254-1258.
37. Thorkildsen C, Neve S, Larsen BD, Meier E & Petersen JS 2003 Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. Journal of Pharmacology and Experimental Therapeutics 307 490-496.
38. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M & Portha B 2002 Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 1443-1452.
39. Wang Q & Brubaker PL, 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 1263-1273.
40. Wang X, Cahill CM, Pineyro MA, Zhou J, Doyle ME & Egan JM 1999 Glucagon-like peptide-1 regulates the beta cell transcription factor PDX-1 in insulinoma cells. Endocrinology 140 4904-4907.
41. Wang X, Zhou J, Doyle ME & Egan JM 2001 Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142 1820-1827.
42. Xu G, Stoffers DA, Habener JF & Bonner-Weir S 1999 Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 2270-2276.